Table 3.
Parameters | Group P
(n = 69) |
Group S
(n = 90) |
P value | Effect size | |
---|---|---|---|---|---|
Chest radiographic changes on aeration | 30 (43.5%) | 24 (26.7%) | 0.013* | 0.35 | |
Changes developed on | Operated lung | 18 (26.1%) | 14 (15.6%) | 0.359 | 0.14 |
Ventilated lung | 7 (10.1%) | 8 (8.9%) | |||
Both lungs | 1 (1.4%) | 2 (2.2%) | |||
Pleural effusion | 29 (42.0%) | 33 (36.7%) | 0.245 | 0.11 | |
Haemothorax | 3 (4.3%) | 0 (0.0%) | 0.080 | 0.16 | |
Pneumonia with overt symptoms and signs | 0 (0.0%) | 0 (0.0%) | - | - |
Data are expressed as the number of patients (percentile). Group P: patients who received pyridostigmine as the reversal agent. Group S: patients who received sugammadex as the reversal agent. Postoperative pain was counted when the measured score was over 3 using the numerical rating scale. Postoperative nausea and vomiting (PONV) were counted as follows from the nursing care records and antiemetics administration history. *: indicates 2-sided P value < 0.05. Effect size: